Shire Q1 2012 Results
April 26, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to March 31,
Financial Highlights Q1 2012(1)
Product sales $1,107 million +24%
Total revenues $1,172 million +21%
Non GAAP operating income $362 million +18%
US GAAP operating income $295 million +11%
Non GAAP diluted earnings per ADS $1.48 +20%
US GAAP diluted earnings per ADS $1.24 +12%
Non GAAP cash generation $310 million +49%
Non GAAP free cash flow $248 million +60%
US GAAP net cash provided by operating activities $257 million +27%
(1) Percentages compare to equivalent 2011 period.
The Non GAAP financial measures included within this release are explained on page 21, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 18 - 20.
Angus Russell, Chief Executive Officer, commented:
"Shire continues to perform strongly with first quarter results in line with our expectations. Product sales increased 24%, Non GAAP operating income was up 18% and Non GAAP diluted earnings per ADS increased 20% to $1.48. Our focus on demonstrating value to the healthcare system through meeting the needs of our patients is continuing to deliver.